---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-024501"
form_type: "8-K"
ticker: "IRIX"
cik: "0001006045"
company_name: "IRIDEX CORP"
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T22:01:32.822546+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# IRIDEX reports record Q3 revenue $14.6M, net loss narrows to $1.8M; maintains FY guidance

## Summary
- Total revenue $14.6M, +10% YoY, record Q3; net loss $1.8M ($0.11/share) vs $2.2M loss ($0.14) prior year.
- Retina product revenue $8.8M (+13% YoY); Cyclo G6 revenue $3.5M (+10%).
- FDA clearance of next-gen Pascal scanning laser system; first shipments in Q4.
- FY revenue guidance maintained at $56-58M; probe units expected ~60,000 (down from 61-63k).
- Cash $15.9M, used $2.1M in quarter including $0.5M inventory pre-orders.

## SEC filing metadata
- accession: 0000950170-22-024501
- form_type: 8-K
- ticker: IRIX
- cik: 0001006045
- company_name: IRIDEX CORP
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1006045/000095017022024501/0000950170-22-024501-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006045/000095017022024501/irix-20221110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-024501
- JSON: https://secwatch.observer/filing/0000950170-22-024501.json
- Plain text: https://secwatch.observer/filing/0000950170-22-024501.txt

## Key facts
- Earnings Releases
  IRIDEX CORP reported fiscal year 2022 results: revenue $56 million to $58 million. Guidance reaffirmed.
  - Period: fiscal year 2022
  - Revenue: $56 million to $58 million
  - Guidance: reaffirmed
  - Result: guidance update
  source text: Iridex continues to expect total revenue for fiscal year 2022 to range from $56 million to $58 million, reflecting growth of 4% to 8% over fiscal year 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1006045/000095017022024501/0000950170-22-024501-index.htm
- Earnings Releases
  IRIDEX CORP reported the third quarter ended October 1, 2022 results: revenue $14.6 million, net income $1.8 million, EPS $0.11 per share.
  - Period: the third quarter ended October 1, 2022
  - Revenue: $14.6 million
  - Net income: $1.8 million
  - EPS: $0.11 per share
  - Result: reported results
  source text: the treatment of glaucoma and retinal diseases, today reported financial results for the third quarter ended October 1, 2022. Third Quarter 2022 Highlights • Total revenue of $14.6 million, a record third quarter revenue, and an increase of 10% over the prior year period • Gross Margin was 44.1% compared to 43.6% in the prior year period • Cyclo G6® product family
  evidence_url: https://www.sec.gov/Archives/edgar/data/1006045/000095017022024501/0000950170-22-024501-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.